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Vaccines improve immunity against a given disease-causing pathogen, primarily by inducing the 
production of neutralizing antibodies against exposed epitopes.  Vaccines are considered of the 
most important medical advances in the history of humanity, resulting in the eradication of smallpox, 
the near-complete elimination of poliomyelitis, and drastic reductions in infection rates of diseases 
including measles, mumps, rubella, and hepatitis (Rappuoli et al., 2011).  Despite these successes, 
infectious diseases caused 18.5% of all human deaths as recently as 2010.  This burden could be 
reduced by the development of effective vaccines against several major pathogens, including human 
immunodeficiency virus (HIV), malaria, and respiratory syncytial virus (RSV), for which successful 
vaccine generation has been problematic. 
A new method, termed epitope-focused vaccine design, holds promise for the development of 
vaccines against these pathogens.  In this approach, protein scaffolds containing epitopes of interest 
are designed using computer algorithms. The specific epitopes are chosen based on those 
recognized by naturally occurring antibodies isolated from patients or animal models of a given 
disease, with the hope that they will induce protective antibody generation in vaccinated individuals.. 
This reverse-engineering approach holds particular potential for the development of vaccines against 
antigenically diverse viruses such as HIV, influenza, and hepatitis C.  To assess the potential of 
epitope-focused vaccine design to generate potent neutralizing antibodies, a team of researchers 
including Dr. Roland Strong (Basic Sciences Division) and Drs. David Baker and William Schief 
(University of Washington) focused on an epitope from the RSV F protein recognized by the 
antibody motavizumab (mota). 
To design a protein scaffold containing the mota epitope, the authors used a computational protein 
design approach termed Fold From Loops (FFL).  They chose a particular structure known as a 
three-helix bundle as the protein template due to its similarity to the helix-turn-helix conformation of 
the epitope recognized by mota.  Through FFL, the researchers designed 40,000 scaffolds, eight of 
which were selected for human-guided optimization.  One design, FFL_001, was computationally 
resurfaced to allow use in immune boosting or to map immune responses to the designed 
scaffolds.  This yielded a set of “FFL_surf” designs.  Six out of eight FFL designs and three out of 
four FFL_surf designs were efficiently produced in E. coli and showed biophysical characteristics  
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consistent with high alpha-helical content, in line with the use of the three-helix bundle as a 
template.  All nine scaffolds generated the correct epitope structure to be recognized and bound by 
mota.  The authors solved the crystal structures of free FFL_005 and FFL_001 bound to mota and 
found that the structures were in good agreement with the design models as well as the structure of 
mota. 
The authors next tested the ability of the scaffolds to induce neutralizing antibodies.  They assayed 
the binding of RSV-positive human serum to FFL_001 and found that three sera reacted with the 
scaffold, while all six sera reacted with RSV F protein.  The authors also tested the ability of three 
scaffolds and a virus-like particle containing multiple copies of FFL_001 to induce RSV-neutralizing 
antibodies in mice and macaques.  RSV-neutralizing activity was not detected in mice, but robust 
neutralizing activity was detected in 7 of 16 macaques after three immunizations and 12 of 16 
macaques after five immunizations.  The researchers then performed functional analysis of 
monoclonal antibodies directed against FFL_001.  These antibodies showed RSV-directed 
neutralizing activities comparable to that of mota. 
These results indicate that computationally designed protein scaffolds bearing epitopes of interest 
can induce potent neutralizing activity, demonstrating the feasibility of epitope-focused vaccine 
design.  "Modern structure-based, rational drug design was conceived, in large part, as a response 
to AIDS. Rational structure-based, reverse-engineered vaccine immunogen design, an approach 
heralded by these results, has as much revolutionary promise," says Dr. Strong. 
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Image provided by Dr. Roland Strong. 
Structure of a second-generation epitope-containing protein scaffold (green helices) bound by the 
RSV-directed antibody motavizumab (green and blue globule). 
 
